Intended for healthcare professionals

Research Article

Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.

Br Med J 1979; 1 doi: (Published 27 January 1979) Cite this as: Br Med J 1979;1:220
  1. R J Walton,
  2. I T Sherif,
  3. G A Noy,
  4. K G Alberti


    An alpha-glucosidehydrolase inhibitor (acarbose; BAY g 5421) taken with food was compared with dummy tablets in seven insulin-treated diabetic patients over eight-hour periods that included breakfast, lunch, and two snacks. Acarbose diminished the postprandial increases in blood glucose, lactate, and pyruvate concentrations and may therefore be of value in the management of insulin-dependent diabetes.